Effect of Glucagon.pptVIP

Table: Patient Demographic No. Of patients 7 Age (yrs) 70 ? 3 Male, N (%) 5 (71.4) Female 2 (28.5) Weight (kgs) 94 ? 9.2 BMI (kg/m2) 30.5 ? 3.2 SBP (mmHg) 125 ? 4 DBP (mmHg) 73.4 ? 4.26 MAP (mmHg) 88.2 ? 4.182 Heart rate (beats/min.) 73 ? 5.34 Regular rhythm, N (%) 7 (100) Diabetes , N (%) 4 (57) Hypertension, N (%) 3 (43) Coronary artery disease, N (%) 7(100) BMI, Body mass index; SBP, Systolic blood pressure; DBP, diastolic blood pressure; MAP, Mean arterial pressure; Table: Patient Demographic (contd) Dyslipidemia 6 (85) Serum Creat. (mg/dL) 1.29 ? 0.107 BUN (mg/dL) 22.7 ? 3.23 HbAIC (%) 6.4 ? 0.252 Baseline BGT (mg/dL) 121.29 ? 10.59 ACE/ARB, N (%) 6(85)* Beta-Blockers, N (%) 6 (85)1 Loop-diuretics, N (%) 4 (57) Spironolactone, N(%) 1 (14.3) Aspirin, N(%) 6 (85)2 Plavix, N(%) 1 (14.3) Statin, (N%) 6 (85) AICD, N (%) 2 (28.5) Pacemaker, N (%) 1 (14.3) * Patient was Allergic to ACE/ARB; 1 Patient developed bradycardia and Mobitz Type I- 20 Heart Block. Inclusion criteria Left ventricular ejection fraction ≤ 40%. Optimum medical therapy for CHF for 6 weeks: ACE inhibitors/ARB and Beta Blockers Loop diuretics ± Spironolactone Stable coronary artery disease Exclusion Criteria Heart failure due to or associated with Uncorrected thyroid disease, Obstructive cardiomyopathy, Pericardial disease, Amyloidosis or Active myocarditis. Hospitalization for acute decompensation of CHF in the past 60 days. Type 1 diabetes mellitus. CABG, LV reduction procedure or cardiomyoplasty within 30 days. Liver enzyme 5 times the upper limit of normal, Prolonged prothrombin time in the absence of systemic anticoagulation therapy at the time of screening. Serum creatinine 3.5 mg/dL or long-term dialysis. Currently on Exenatide ( Byetta*) END POINTS Primary Short term change in Left Ventricular Ejection Fraction, % Secondary End diastolic volume index (EDVI). End systolic volume index (ESVI) Hemodynamic response. SBP, DBP, MAP, HR. Short term side effects. Results. Table 4